Sim Lab: Publications
Publications:
Flores-Fernandez JM, Pesch V, Sriraman A, Chimal-Juarez E, Amidian S, Wang X, Duckering C, Fang A, Reithofer S, Ma L, Cortez L, Sim V, Wille H. Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson’s disease and related disorders. Bioentineering & Translational Medicine. IN PRESS. doi: 10.1002/btm2.10665. 2024.
Caughey B and Sim VL. Prions, in: Fields Virology Fundamentals, 7th edition. P.M. Howley and D.M. Knipe, (Eds.), Wolters Kluwer. 2023.
Garza MC, Kang S-G, Kim C, Monleon E, van der Merwe J, Kramer DA, Fahlman R, Sim VL, Aiken J, McKenzie D, Cortez LM, Wille H. In vitro and in vivo evidence towards fibronectin's protective effects against prion infection. International Journal of Molecular Sciences. 24(24):17525. doi: 10.3390/ijms242417525. 2023.
Willows ST, Semenchenko V, Norman G, Woodside MT, Sim V, Kulka M. Mast cell proteases cleave prion proteins and a recombinant immunoglobulin against PrP can activate human mast cells. The Journal of Immunology. 2023 Mar 20;ji2200726. doi: 10.4049/jimmunol.2200726. 2023.
Cortez LM, Morrison AJ, Garen CR, Patterson S, Uyesugi T, Petrosyan R, Sekar RV, Harms MJ, Woodside MT, Sim VL. Probing the origin of prion protein misfolding via reconstruction of ancestral proteins. Protein Science. 2022 Oct 18;e4477. doi: 10.1002/pro.4477. 2022.
Binczyk NM, Smith MJ, Nathoo N, Sim VL, Jeffery D, Jivraj I. Visual disturbances and headache as presenting symptoms of Creutzfeldt-Jakob disease. Journal of Neuro-Ophthalmology. 42(2):e488-e490. doi.org/10.1097/WNO.0000000000001293. 2022.
Wu Q, Cortez L, Kamali-Jamil R, Sim V, Wille H, Kar S. Implication of exosomes derived from cholesterol-accumulated astrocytes in Alzheimer's disease pathology. Disease Models & Mechanisms. 14(10):dmm048929. doi: 10.1242/dmm.048929. 2021.
Cortez LM, Nemani SK, Velasquez CD, Sriraman A, Wang YL, Wille H, McKenzie D, Sim VL. Asymmetric-flow field-flow fractionation of prions reveals a strain-specific continuum of quaternary structures with protease resistance developing at a hydrodynamic radius of 15 nm. PLoS Pathogens. 17(6):e1009703. doi.org/10.1371/journal.ppat.1009703. 2021.
Luk CC, Mathiason CK, Orru CD, Jansen GH, Thiele A, Caughey B, Sim VL. Creutzfeldt-Jakob Disease in Pregnancy: the use of modified RT-QuIC to determine infectivity in placental tissues. Prion. 15(1):107-111. doi.org/10.1080/19336896.2021.1933872. 2021.
Lucena DD, Kruse N, Thune K, Schmitz M, Villar-Pique A, da Cunha EG, Hermann P, Perez OL, Benito PA, Ladogana A, Laqra MC, Vidal E, Riggert J, Pineau H, Sim V, Zetterberg H, Blennow K, del Rio JA, Moreno AM, Espinosa JC, Torres JM, Mollenhauer B, Ferrer I, Zerr I, Llorens F. TREM2 expression in the brain and biological fluids in prion diseases. Acta Neuropathologica. 141:841-859. doi.org/10.1007/s00401-021-02296-1. 2021.
Ali T, Hannaoui S, Nemani S, Tahir W, Zemlyankina I, Cherry P, Shim SY, Sim V, Schaetzl HM, Gilch S. Oral administration of repurposed drug targeting Cyp46A1 increases survival times in preclinical trials towards treatment of prion disease. Acta Neuropathologica Communications. 9(1):58. doi.org/10.1186/s40478-021-01162-1. 2021.
Nemani SK, Myskiw JL, Lamoureux L, Booth SA, Sim VL. Exposure risk of chronic wasting disease in humans. Viruses. 12(12);1454. doi.org/10.3390/v12121454. 2020.
Jeon K, Joseph JT, Jansen GH, Peterson A, Knox JD, Sim VL. Creutzfeldt-Jakob Disease with a five-year clinical course, multicentric cerebellar prion plaques and prior history of biopsy-proven primary angiitis of the central nervous system: a case for iatrogenic exposure? Viruses. 12(12):E1411. doi.org/10.3390/v12121411. 2020.
Eskandari-Sedighi G, Cortez L, Yang J, Daude N, Shmeit K, Sim V, Westaway D. Quaternary structure changes for PrPSc predate PrPC down-regulation and neuronal death during progression of experimental scrapie disease. Molecular Neurobiology. 58:375-390. doi.org/10.1007/s12035-020-02112-z. 2020.
Pineau H and Sim VL. POSCAbilities: The Application of the Prion Organotypic Slice Culture Assay to Neurodegenerative Disease Research. Biomolecules. 10(7). 10.3390/biom10071079. 2020.
Nemani SK, Xiao X, Cali I, Cracco L, Puoti G, Nigro M, Lavrich J, Singh AB, Appleby BS, Sim VL, Notari S, Surewicz W, Gambetti P. A novel mechanism of phenotypic heterogeneity in Creutzfeldt-Jakob disease. Acta Neuropath Communications. 8(85). doi.org/10.1186/s40478-020-00966-x. 2020.
Esmaili M, Tancowny BP, Wang X, Moses A, Cortez L, Sim V, Wille H, Overduin M. Native nanodiscs formed by styrene maleic acid copolymer derivatives help recover infectious prion multimers bound to brain-derived lipids. J Biol Chem. 295(25):8460-8469. doi.org/10.1074/jbc.RA119.012348. 2020.
Lau D, Cooper R, Chen J, Sim VL, McCombe JA, Tyrrell GJ, Bhargava R, Ada B, Chapman E, Croxen, MA, Garady C, Antonation K, van Landeghem FKH, Ip S, Saxinger L. Mycobacterium chimaera encephalitis post-cardiac surgery: A new syndrome. Clinical Infectious Diseases. ciz497. doi.org/10.1093/cid/ciz497. 2019.
Gushue D, Herbst A, Sim V, McKenzie D, Aiken, JM. 14-3-3 and enolase abundances in the CSF of Prion diseased rats. Prion. doi.org/10.1080/19336896.2018.1513317. 2018.
Norman G, Campeau J, Sim VL. High dose and delayed treatment with bile acids ineffective in RML prion-infected mice. Antimicrob Agents Chemother. 62(8). pii: AAC.00222-18. doi.org/10.1128/AAC.00222-18. 2018.
Foroutanpay BV, Kumar J, Kang SG, Danaei N, Westaway D, Sim VL, Kar S. The effects of N-terminal mutations on beta-amyloid peptide aggregation and toxicity. Neuroscience. 20(379):177-188. doi.org/10.1016/j.neuroscience.2018.03.014. 2018.
Gupta AN, Neupane K, Rezajooei N, Cortez L, Sim V, Woodside MT. Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion protein. Nat Commun. 7:12058. doi.org/10.1038/ncomms12058. 2016.
Mostofi E, Schievink WI, Sim VL. Dural Reduction Surgery: A Treatment Option for Frontotemporal Brain Sagging Syndrome. Can J of Neuro Sci. 43:593-5. 2016.
Kang S-G, Kim C, Cortez LM, Yang J, Garza MC, Wille H, Sim VL, Westaway D, McKenzie D, Aiken J. Toll-Like Receptor-Mediated Immune Response Inhibits Prion Propagation. Glia. doi.org/10.1002/glia.22973. 2016.
Wolf H, Hossinger A, Fehlinger A, Buettner S, Sim VL, McKenzie D, Vorberg I. Deposition pattern and subcellular distribution of disease-associated prion protein in cerebellar organotypic slice cultures infected with scrapie. Front Neurosci. 9:410. doi.org/10.3389/fnins.2015.00410. 2015.
Kumar J, Namsechi R, and Sim VL. Structure-based peptide design to modulate amyloid beta aggregation and reduce cytotoxicity. PLoS ONE. 10(6):e0129087. 2015.
Cortez LM, Campeau J, Norman G, Kalayil M, Van der Merwe J, McKenzie D, and Sim VL. Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease. J Virol. pii: JVI.01165-15. 2015.
Cortez LM and Sim VL. The therapeutic potential of chemical chaperones in protein folding diseases. Prion. 8(2): pii: 28938. 2014.
Kumar J and Sim VL. D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. Prion. 8(1): 119-24. 2014.
Walsh P, Vanderlee G, Yau J, Campeau J, Sim VL, Yip CM, and Sharpe S. The mechanism of membrane disruption by cytotoxic amyloid oligomers formed by PrP(106-126) is dependent on bilayer composition. J. Biol. Chem. 2014.
Campeau JL, Wu G, Bell JR, Rasmussen J, and Sim VL. Loss of dendritic spines in prion-infected organotypic mouse cerebellar cultures. PLoS ONE. 8(12): e81776. 2013.
Herbst A, Banser P, Velasquez CD, Mays CE, Sim VL, Westaway D, Aiken J, and McKenzie D. Infectious Prions Accumulate to High Levels in Non Proliferative C2C12 Myotubes. PLoS Pathog. 9(11): e1003755. 2013.
Cortez LM and Sim VL. Implications of Prion Polymorphisms. Prion. 7(4):7(4):276-279. 2013.
Sim VL. Prion Diseases, in: A. Jackson, (Ed.), Viral Infections of the Human Nervous System. 371-401. 2013.
Cortez LM , Kumar J , Renault L , Young HS , and Sim VL. Mouse prion protein polymorphism 108F/189V affects the kinetics of fibril formation and the response to seeding; evidence for a two step nucleation polymerization mechanism. J. Biol. Chem. 288(7):4772-81. 2013.
Barton KA, Sim VL, Hughson AG, and Caughey B. Analysis of Prions by Field-Flow Fractionation, in: S.K.R. Williams and K.D. Caldwell, (Eds.), Field-Flow Fractionation in Biopolymer Analysis. 139-149. 2012.
Sim VL. Prion Disease: Chemotherapeutic Strategies. Infect. Disord. Drug Targets. 12:144-160. 2012.
Torres-Bugeau CM, Avila CL, Raisman-Vozari R, Papy-Garcia D, Itri R, Barbosa LRS, Cortez L, Sim VL, and Chehin RN. Characterization of Heparin-induced Glyceraldehyde-3-phosphate Dehydrogenase Early Amyloid-like Oligomers and Their Implication on Alpha-Synuclein Aggregation. J. Biol. Chem. 287(4):2398-409. 2012.
Caughey B, Sim VL, Taubner L, Wilham JM, Orrú C, Christensen LB, Barton KA, Raymond GJ, Raymond LD, and Hughson AG. Prion biochemistry, detection & therapeutics, in: V. St. Georgiev, (Ed.), National Institute of Allergy and Infectious Diseases, NIH: Volume 3, Intramural Research. Infectious Disease, 2010, Volume 3, Part 10, 299-303. 2010.
Sim VL and Caughey B. Prion disease therapy: trials and tribulations, in: M. Ramirez-Alvarado, J.W. Kelly, and C.M. Dobson, (Eds.), Protein Misfolding Diseases: Current and Emerging Principles and Therapies. 259-303. 2010.
Sim VL and Caughey B. Recent advances in prion chemotherapeutics. Infect. Disord. Drug Targets. 9:81-91. 2009.
Sim VL and Caughey B. Ultrastructures and strain comparison of under-glycosylated scrapie prion fibrils. Neurobiol. Aging. 30(12):2031-42. 2009.
Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, Priola SA, and Caughey B. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nature Methods. 4(8):645-650. 2007.
Tahiri-Alaoui A, Sim VL, Caughey B, and James W. Molecular heterosis of prion protein beta oligomers: A potential mechanism of human resistance to disease. J. Biol. Chem. 281(45):34171-34178. 2006.
Atarashi R, Sim VL, Nishida N, Caughey B, and Katamine S. Prion strain-dependent differences in conversion of mutant prion proteins in cell culture. J. Virol. 80:7854-7862. 2006.
Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, and Caughey B. The most infectious prion protein particles. Nature. 437:257-261. 2005.
Stay tuned for more coming to a journal near you (hopefully!)
Last updated: 2024-03-28